Status not kept up to date
MicroPort® Endoscopic Instrument Control System to Accomplish Robotic-assisted Surgery in Urology
NCT04404738 · Changhai Hospital · Updated 1 Sept 2020
- What is being tested
- MicroPort® robot-assisted laparoscopic surgery; da Vinci robot-assisted laparoscopic surgery
- For
- Robotic Surgical Procedures; Prostatectomy; Nephrectomy
- Kind of study
- Tests a treatment or device on volunteers. No drug phase (a device or procedure study).
- Who can join
- Ages 18 years to 80 years. About 104 people. The full rules are on the registry page.
- Where
- China (4 sites)
- When
- Starts or started 29 June 2020, ends Dec 2022. Registered 27 May 2020.
- Results
- None posted yet.
In the researchers' words
Laparoscopy, now virtually completely, was replaced with robotic surgery in uro-oncological surgery in the world. And given the significant increase in the number of robotic surgeries for prostate, bladder and kidney cancer, it is now a major domain in oncological surgery. Microport MedBot Inc. has independently developed a domestic surgical robot in China. Therefore, the purpose of the study is to evaluate the safety and efficacy of the Chinese robot when applied to surgery in oncology.
Sites
- Renji Hospital Affiliated to Shanghai Jiaotong University School of MedicineShanghai, China
- The first affiliated hospital of naval medical university (Shanghai changhai hospital)Shanghai, China
- Zhongshan Hospital Affiliated to Fudan UniversityShanghai, China
- Zhejiang Provincial People's HospitalZhejiang, China